Table 1.

Summary of subjects who received RTS,S and CHMI included in analyses.

Clinical Trial	Reference	Adjuvant	Schedule	Sample Size
WRMAL-003	[15]	AS02	RRR	19
WRMAL-012	[16]	AS02	RRR	20
MAL027	[17]	AS01 AS02	RRR RRR	26 33
MAL068	[18]	AS01 AS01	RRR ARR	21 25
MAL071	[4]	AS01 AS01	RRR RRr	16 30
VAC055	[19]	AS01 AS01	RRR RARR + MVA	15 17

‘Adjuvant’ indicates adjuvant included in the RTS,S formulation. ‘Schedule’ denotes the vaccination schedule: the standard 0/1/2 month RTS,S regimen (RRR); an adenovirus prime followed by two RTS,S doses after 1/2 months (ARR); the delayed fractional dose RTS,S regimen where the final dose was reduced and delayed to 7 months (RRr); or, the standard 0/1/2 month RTS,S regimen with adenovirus and modified vaccinia Ankara viral vectors against ME-TRAP at two weeks and 10 weeks, respectively (RARR + MVA).